Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05703425 · ClinicalTrials.gov registry record · Phase 2
The Effect of Sulfasalazine on CRH Levels in Pregnant Women
A Phase 2 study of Preterm Birth, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05703425: Recruiting Phase 2 study of Preterm Birth, sponsored by Rutgers, The State University of New Jersey.
NCT05703425 is a Phase 2 study of Preterm Birth that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 50 participants, below the 4,408-participant average among 39 other Preterm Birth trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05703425, a Phase 2 study of Preterm Birth, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth? * Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls? Consenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.
Primary Outcome
CRH will be assessed at 28, 32, and 36 weeks gestation
Conditions Studied
Interventions
- DRUG Sulfasalazine
Study Locations (1)
New Jersey
- Rutgers Robert Wood Johnson Medical School - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT05703425 shows while recruiting
NCT05703425 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,408-participant average among 39 other Preterm Birth trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Preterm Birth appearing as the primary indexed condition, and to 1 intervention - of which Sulfasalazine is the first listed.
NCT05703425 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT05703425 about?
NCT05703425 is a clinical study titled "The Effect of Sulfasalazine on CRH Levels in Pregnant Women". The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of pr...
What is the current status of trial NCT05703425?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-03-01. Estimated completion is 2026-06-30.
What conditions does trial NCT05703425 study?
This clinical trial studies the following conditions: Preterm Birth.
What interventions are being tested in trial NCT05703425?
The interventions under investigation include: Sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT05703425?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05703425 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Preterm Birth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05703425's enrollment target sits among peer trials
50 33rd of 39 higher than 7 of 39 other Preterm Birth trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Preterm Birth trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Reducing Preterm Births in Underserved Pregnant Women
COMPLETED · Phase 2
-
Transition From Donor Milk: a Feasibility Study
RECRUITING · NA
-
Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)
RECRUITING · Phase 4
-
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
RECRUITING · NA
-
Daily Aspirin vs Split Dosing in High-risk Pregnancies (DASH)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI